3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma
2
Breast Neoplasms
2
Vomiting
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Postoperative Nausea and Vomiting
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Liposarcoma
1
Leukemia, Hairy Cell
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Adenocarcinoma, Mucinous
1
Interventions
pembrolizumab
137
Cisplatin
75
Cetuximab
51
Carboplatin
49
Paclitaxel
39
Nivolumab
38
Radiotherapy
37
Docetaxel
34
Radiotherapy, Intensity-Modulated
30
Magnetic Resonance Spectroscopy
25
Specimen Handling
20
Fluorouracil
20
Platinum
14
1,2-diaminocyclohexaneplatinum II citrate
13
Taxes
12
cemiplimab
11
Radiation
11
Ipilimumab
11
atezolizumab
10
Surgical Procedures, Operative
10
Drug Therapy
10
Biopsy
9
durvalumab
8
Radiosurgery
8
130-nm albumin-bound paclitaxel
8
tislelizumab
7
Standard of Care
7
Chemoradiotherapy
7
Albumin-Bound Paclitaxel
7
Immune Checkpoint Inhibitors
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Famotidine
×
1 year
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled